| P50 | author | Marilyn Huestis | Q60467738 |
| P2093 | author name string | Dayong Lee | |
| P2860 | cites work | The neurobiology and evolution of cannabinoid signalling | Q24522320 |
| | Cannabinoid receptor localization in brain | Q24558751 |
| | Marijuana use and motor vehicle crashes | Q24633868 |
| | Cannabinoid pharmacology: the first 66 years | Q24670395 |
| | Cannabis effects on driving skills | Q26860495 |
| | Simultaneous identification of 2-carboxy-tetrahydrocannabinol, tetrahydrocannabinol, cannabinol and cannabidiol in oral fluid | Q28290089 |
| | Detection of cannabis use in drivers with the drugwipe device and by GC-MS after Intercept device collection | Q28292396 |
| | Effect of cannabis usage on the oral environment: a review | Q28306568 |
| | Psychomotor function in chronic daily Cannabis smokers during sustained abstinence | Q28484765 |
| | Analysis of Delta9-tetrahydrocannabinol in oral fluid samples using solid-phase extraction and high-performance liquid chromatography-electrospray ionization mass spectrometry. | Q30350854 |
| | Measuring substance use in the club setting: a feasibility study using biochemical markers. | Q30412845 |
| | Driving under the influence of drugs -- evaluation of analytical data of drugs in oral fluid, serum and urine, and correlation with impairment symptoms | Q30992865 |
| | Cytochrome P450 expression and related metabolism in human buccal mucosa. | Q32128984 |
| | Determination of delta 9-tetrahydrocannabinol in human blood and saliva by high-performance liquid chromatography with amperometric detection | Q69816730 |
| | Excretion patterns of cannabinoid metabolites after last use in a group of chronic users | Q69912869 |
| | Detection of recent cannabis use by saliva delta 9-THC radioimmunoassay | Q70081563 |
| | Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women | Q70157627 |
| | Detection of delta 9-THC in saliva by capillary GC/ECD after marihuana smoking | Q70161362 |
| | Effects of cannabis smoking on oral soft tissues | Q70692911 |
| | Determination of delta 9-tetrahydrocannabinol from human saliva by tandem immunoaffinity chromatography--high-performance liquid chromatography | Q71251300 |
| | Metabolism of phenytoin by the gingiva of normal humans: the possible role of reactive metabolites of phenytoin in the initiation of gingival hyperplasia | Q71571831 |
| | Validity of self-reported drug use in chronic pain patients | Q73090250 |
| | Detection of cannabis in oral fluid (saliva) and forehead wipes (sweat) from impaired drivers | Q73106963 |
| | On-site testing of saliva and sweat with Drugwipe and determination of concentrations of drugs of abuse in saliva, plasma and urine of suspected users | Q73945522 |
| | Detection of marijuana use by oral fluid and urine analysis following single-dose administration of smoked and oral marijuana | Q74354103 |
| | Differentiating new marijuana use from residual drug excretion in occasional marijuana users | Q77464303 |
| | Detection of THCA in oral fluid by GC-MS-MS | Q79395971 |
| | Controlled substance abuse and illicit drug use in chronic pain patients: An evaluation of multiple variables | Q80052401 |
| | Pharmacokinetic properties of delta9-tetrahydrocannabinol in serum and oral fluid | Q80501900 |
| | Validated method for the simultaneous determination of Delta9-THC and Delta9-THC-COOH in oral fluid, urine and whole blood using solid-phase extraction and liquid chromatography-mass spectrometry with electrospray ionization | Q80574393 |
| | Oral fluid drug tests: effects of adulterants and foodstuffs | Q81827054 |
| | Oral fluid drug testing of chronic pain patients. I. Positive prevalence rates of licit and illicit drugs | Q82057910 |
| | Simultaneous determination of Δ9-tetrahydrocannabinol and 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in oral fluid using isotope dilution liquid chromatography tandem mass spectrometry | Q82693047 |
| | An analytical evaluation of eight on-site oral fluid drug screening devices using laboratory confirmation results from oral fluid | Q83021083 |
| | Oral fluid drug testing of chronic pain patients. II. Comparison of paired oral fluid and urine specimens | Q83455351 |
| | Development of an electrospray LC-MS/MS method for quantification of Δ(9) -tetrahydrocannabinol and its main metabolite in oral fluid | Q83532947 |
| | Analysis of tetrahydrocannabinol and its metabolite, 11-nor-Δ⁹-tetrahydrocannabinol-9-carboxylic acid, in oral fluid using liquid chromatography with tandem mass spectrometry | Q83987709 |
| | Cannabinoids in oral fluid following passive exposure to marijuana smoke | Q84564817 |
| | Estimating equivalent cutoff thresholds for drugs in blood and oral fluid using prevalence regression: a study of tetrahydrocannabinol and amphetamine | Q84579441 |
| | Oral fluid for workplace drug testing: laboratory implementation | Q84941521 |
| | Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure | Q37389692 |
| | Simultaneous quantification of Δ(9)-tetrahydrocannabinol, 11-nor-9-carboxy-tetrahydrocannabinol, cannabidiol and cannabinol in oral fluid by microflow-liquid chromatography-high resolution mass spectrometry | Q37570138 |
| | Testing for cannabis in the work-place: a review of the evidence. | Q37733722 |
| | Conventional and Alternative Matrices for Driving Under The Influence of Cannabis: Recent Progress and Remaining Challenges | Q37810239 |
| | Prevalence of illicit drug use among the Italian athlete population with special attention on drugs of abuse: a 10-year review | Q37833561 |
| | Neurochemical basis of cannabis addiction. | Q37844898 |
| | Oral fluid cannabinoids in chronic, daily Cannabis smokers during sustained, monitored abstinence | Q37890173 |
| | Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity | Q38003185 |
| | Illicit drug use correlates with negative urine drug test results for prescribed hydrocodone, oxycodone, and morphine. | Q38045245 |
| | Potency trends of Δ9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. | Q38431693 |
| | Cannabis (Marijuana) - Effects on Human Performance and Behavior | Q38563374 |
| | Metabolism of Δ1-tetrahydrocannabinol by the isolated perfused dog lung. Comparison with in vitro liver metabolism | Q39068711 |
| | Cannabis use for chronic non-cancer pain: results of a prospective survey | Q39397282 |
| | Hormones in saliva | Q39727802 |
| | Detection of Delta9-tetrahydrocannabinol and amphetamine-type stimulants in oral fluid using the Rapid Stat point-of-collection drug-testing device | Q39929567 |
| | Screening for drugs in oral fluid: drug driving and illicit drug use in a sample of Queensland motorists. | Q39978511 |
| | Constituents of Cannabis sativa L. XVII. A review of the natural constituents | Q40284493 |
| | Cytochrome P450 expression and activities in human tongue cells and their modulation by green tea extract. | Q40475600 |
| | Proteome analysis of glandular parotid and submandibular-sublingual saliva in comparison to whole human saliva by two-dimensional gel electrophoresis | Q33231209 |
| | The role of alternative specimens in toxicological analysis. | Q33338053 |
| | Simultaneous quantification of cannabinoids and metabolites in oral fluid by two-dimensional gas chromatography mass spectrometry | Q33770190 |
| | Adverse effects of cannabis and cannabinoids | Q33837221 |
| | Abstinence symptoms during withdrawal from chronic marijuana use. | Q33928980 |
| | Pharmacology and effects of cannabis: a brief review | Q33931252 |
| | Dose-related neurocognitive effects of marijuana use. | Q33962455 |
| | The time course and significance of cannabis withdrawal | Q33967997 |
| | Dose related risk of motor vehicle crashes after cannabis use. | Q33975160 |
| | Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug | Q33995048 |
| | Use of alcohol and drugs by Norwegian employees: a pilot study using questionnaires and analysis of oral fluid | Q34008868 |
| | Neuropsychological performance in long-term cannabis users | Q34092892 |
| | Validation of an enzyme immunoassay for detection and semiquantification of cannabinoids in oral fluid | Q34107928 |
| | Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users | Q34153831 |
| | Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis | Q34155916 |
| | Cannabidiol: an overview of some pharmacological aspects | Q34157378 |
| | Pharmacokinetics and pharmacodynamics of cannabinoids | Q34185013 |
| | Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease | Q34188446 |
| | Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers | Q34199610 |
| | Cannabis intoxication and fatal road crashes in France: population based case-control study. | Q34203847 |
| | Blurred boundaries: the therapeutics and politics of medical marijuana | Q34251969 |
| | Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects | Q34253509 |
| | Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. | Q34266560 |
| | A review of drug use and driving: epidemiology, impairment, risk factors and risk perceptions | Q34348610 |
| | Saliva: its secretion, composition and functions | Q34420780 |
| | Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol | Q34510863 |
| | Cannabinoids: potential anticancer agents | Q34542671 |
| | Urine drug testing of chronic pain patients: licit and illicit drug patterns | Q34600233 |
| | Molecular biology of cannabinoid receptors | Q34673034 |
| | Cannabinoid-based medicines for neurological disorders--clinical evidence | Q34704890 |
| | Saliva and gastrointestinal functions of taste, mastication, swallowing and digestion | Q34728951 |
| | Drug testing in oral fluid. | Q35053485 |
| | Identifying new cannabis use with urine creatinine-normalized THCCOOH concentrations and time intervals between specimen collections | Q35175102 |
| | Extrahepatic metabolism of drugs in humans | Q40743025 |
| | Validity of self-reported drug use in high risk populations: a meta-analytical review | Q41148641 |
| | Tolerance and disposition of tetrahydrocannabinol in man | Q41549761 |
| | The validity of self-reported drug use in survey research: an overview and critique of research methods | Q41551156 |
| | Creatinine VIII: Saliva levels of endogenous “true” creatinine in normal subjects | Q41617381 |
| | Salivary THC following cannabis smoking correlates with subjective intoxication and heart rate | Q41779586 |
| | Cannabis smoke condensate III: the cannabinoid content of vaporised Cannabis sativa | Q41993429 |
| | Pharmacokinetics of delta 9-tetrahydrocannabinol in rabbits following single or multiple intravenous doses | Q42030966 |
| | Relationship of Delta 9-tetrahydrocannabinol concentrations in oral fluid and plasma after controlled administration of smoked cannabis | Q42163427 |
| | Passive cannabis smoke exposure and oral fluid testing | Q42163691 |
| | Simultaneous detection of some drugs of abuse in saliva samples by SPME technique | Q42168022 |
| | The Prevalence of Alcohol and Drugs in Sampled Oral Fluid is Related to Sample Volume | Q42914944 |
| | The effect of alcohol, THC and their combination on perceived effects, willingness to drive and performance of driving and non-driving tasks. | Q42930353 |
| | Recent substance intake among patients admitted to acute psychiatric wards: physician's assessment and on-site urine testing compared with comprehensive laboratory analyses | Q42970029 |
| | Pharmacokinetic properties of delta9-tetrahydrocannabinol in oral fluid of occasional and chronic users | Q43064563 |
| | Comparison of drug concentrations in blood and oral fluid collected with the Intercept sampling device | Q43064566 |
| | The effects of cannabis and alcohol on simulated arterial driving: Influences of driving experience and task demand | Q43104529 |
| | Analysis of cannabis in oral fluid specimens by GC-MS with automatic SPE. | Q43178844 |
| | Evaluation of on-site oral fluid screening using Drugwipe-5(+), RapidSTAT and Drug Test 5000 for the detection of drugs of abuse in drivers. | Q43242431 |
| | Simultaneous screening and quantification of 29 drugs of abuse in oral fluid by solid-phase extraction and ultraperformance LC-MS/MS. | Q43268353 |
| | Forum: Decriminalization of cannabis | Q43457758 |
| | Concordance between verbal report and urine screen of recent marijuana use in adolescents | Q43676500 |
| | Illicit drug use in the pain patient population decreases with continued drug testing. | Q43978442 |
| | Effects of oral THC maintenance on smoked marijuana self-administration | Q44070878 |
| | Oral fluid testing for drugs of abuse: positive prevalence rates by Intercept immunoassay screening and GC-MS-MS confirmation and suggested cutoff concentrations | Q44261993 |
| | Cannabidiol interferes with the effects of Δ9-tetrahydrocannabinol in man | Q44323036 |
| | Prevalence and disposition of drugs of abuse and opioid treatment drugs in oral fluid | Q44336787 |
| | Behavioral Monitoring and Urine Toxicology Testing in Patients Receiving Long-Term Opioid Therapy | Q44342865 |
| | Solid-phase micro-extraction-gas chromatography-mass spectrometry and headspace-gas chromatography of tetrahydrocannabinol, amphetamine, methamphetamine, cocaine and ethanol in saliva samples | Q44426514 |
| | Sporting activity and drug use: Alcohol, cigarette and cannabis use among elite student athletes | Q44557287 |
| | Prescription and illicit psychoactive drugs in oral fluid--LC-MS/MS method development and analysis of samples from Brazilian drivers. | Q44626150 |
| | The involvement of drugs in drivers of motor vehicles killed in Australian road traffic crashes. | Q44672030 |
| | Recovery of spiked Δ9-tetrahydrocannabinol in oral fluid from polypropylene containers | Q44869076 |
| | Relationship between oral fluid and blood concentrations of drugs of abuse in drivers suspected of driving under the influence of drugs | Q44922765 |
| | Epidemiology of alcohol and other drug use among motor vehicle crash victims admitted to a trauma center | Q44995180 |
| | Drug abuse among workers in Brazilian regions | Q45018431 |
| | Development and validation of a method for the quantitation of Delta9tetrahydrocannabinol in oral fluid by liquid chromatography electrospray-mass-spectrometry. | Q45068670 |
| | The impact of cannabis on driving. | Q45116757 |
| | A snapshot of workplace drug testing in the UK. | Q45256144 |
| | Workplace drug testing in Italy - critical considerations | Q45363615 |
| | Detection of conjugated 11-nor-Delta9-tetrahydrocannabinol-9-carboxylic acid in oral fluid. | Q45976179 |
| | Ultra-sensitive measurements of 11-Nor-δ(9)-tetrahydrocannabinol-9-carboxylic acid in oral fluid by microflow liquid chromatography-tandem mass spectrometry using a benchtop quadrupole/orbitrap mass spectrometer. | Q46021553 |
| | Stability of drugs of abuse in oral fluid collection devices with purpose of external quality assessment schemes. | Q46077920 |
| | Analytical procedure for the determination of the marijuana metabolite 11-nor-Delta9-tetrahydrocannabinol-9-carboxylic acid in oral fluid specimens | Q46092096 |
| | Evaluation of the Cozart DDSV test for cannabis in oral fluid | Q46155767 |
| | Letter to the editor regarding "Simultaneous determination of ∆9-tetrahydrocannabinol and 11-nor-9-carboxy-∆9-tetrahydrocannabinol in oral fluid using isotope dilution liquid chromatography tandem mass spectrometry". | Q46174361 |
| | Multiclass analysis of illicit drugs in plasma and oral fluids by LC-MS/MS. | Q46266054 |
| | Brain microsomal oxidation of delta 8- and delta 9-tetrahydrocannabinol | Q46373604 |
| | Prevalence of alcohol and drugs among Norwegian motor vehicle drivers: a roadside survey | Q46400770 |
| | Analysis of alcohol and drugs in oral fluid from truck drivers in Norway | Q46410866 |
| | Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users | Q46417441 |
| | Validated toxicological determination of 30 drugs of abuse as optimized derivatives in oral fluid by long column fast gas chromatography/electron impact mass spectrometry | Q46418608 |
| | Drug testing in oral fluid-evaluation of sample collection devices | Q46464354 |
| | Oral fluid testing for drugs of abuse | Q35190524 |
| | Disposition of cannabinoids in oral fluid after controlled around-the-clock oral THC administration | Q35209227 |
| | Concentration dependent effects of tobacco particulates from different types of cigarettes on expression of drug metabolizing proteins, and benzo(a)pyrene metabolism in primary normal human oral epithelial cells | Q35239248 |
| | Factors associated with premature mortality among young injection drug users in Vancouver | Q35585416 |
| | Cannabinoids and metabolites in expectorated oral fluid following controlled smoked cannabis | Q35870084 |
| | Oral fluid as a diagnostic tool | Q35970366 |
| | Drug violations and aviation accidents: findings from the US mandatory drug testing programs | Q36082091 |
| | Oral fluid collection: the neglected variable in oral fluid testing | Q36130556 |
| | Review: The physiology of saliva and transfer of drugs into saliva | Q36156161 |
| | Illicit drug use and injuries: A review of emergency room studies | Q36267395 |
| | Differentiating new cannabis use from residual urinary cannabinoid excretion in chronic, daily cannabis users | Q36288375 |
| | Long term marijuana users seeking medical cannabis in California (2001-2007): demographics, social characteristics, patterns of cannabis and other drug use of 4117 applicants | Q36329247 |
| | Plant, synthetic, and endogenous cannabinoids in medicine | Q36366922 |
| | Psychomotor performance, subjective and physiological effects and whole blood Δ⁹-tetrahydrocannabinol concentrations in heavy, chronic cannabis smokers following acute smoked cannabis | Q36471630 |
| | Toxicokinetics of drugs of abuse: current knowledge of the isoenzymes involved in the human metabolism of tetrahydrocannabinol, cocaine, heroin, morphine, and codeine | Q36508621 |
| | The cannabinoid receptor: biochemical, anatomical and behavioral characterization | Q36605535 |
| | Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration? | Q36729404 |
| | The U.S. Mandatory Guidelines for Federal Workplace Drug Testing Programs: current status and future considerations | Q36791834 |
| | The role of urine toxicology in chronic opioid analgesic therapy | Q37013338 |
| | Marijuana's interaction with brain reward systems: update 1991. | Q37028121 |
| | Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration | Q37029480 |
| | Cannabis in sport: anti-doping perspective | Q37029485 |
| | Cannabinoid disposition in oral fluid after controlled smoked cannabis | Q37029531 |
| | Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers' blood on per se drugged driving laws | Q37029547 |
| | Cannabinoid stability in authentic oral fluid after controlled cannabis smoking | Q37029564 |
| | Saliva composition and functions: a comprehensive review | Q37107877 |
| | Current developments in drug testing in oral fluid | Q37119661 |
| | The prevalence of cannabis-involved driving in California | Q37127803 |
| | 11-Nor-9-carboxy-∆9-tetrahydrocannabinol quantification in human oral fluid by liquid chromatography-tandem mass spectrometry | Q37172153 |
| | Guidelines for research on drugged driving | Q37212779 |
| | Oral fluid and plasma cannabinoid ratios after around-the-clock controlled oral Δ(9)-tetrahydrocannabinol administration | Q37331681 |
| | Cannabinoids and metabolites in expectorated oral fluid after 8 days of controlled around-the-clock oral THC administration | Q37347101 |
| | On-site test for cannabinoids in oral fluid | Q37355994 |
| | Proficiency testing (external quality assessment) of drug detection in oral fluid | Q46535178 |
| | Determination of illicit and medicinal drugs and their metabolites in oral fluid and preserved oral fluid by liquid chromatography-tandem mass spectrometry. | Q46592842 |
| | Effects of THC on driving performance, physiological state and subjective feelings relative to alcohol | Q46609528 |
| | Quantitative analysis of delta9-tetrahydrocannabinol in preserved oral fluid by liquid chromatography-tandem mass spectrometry | Q46613827 |
| | Passive cannabis smoke exposure and oral fluid testing. II. Two studies of extreme cannabis smoke exposure in a motor vehicle | Q46898639 |
| | Stability of Delta(9)-tetrahydrocannabinol (THC) in oral fluid using the Quantisal collection device | Q46901597 |
| | Driving under the influence of cannabis: pitfalls, validation, and quality control of a UPLC-MS/MS method for the quantification of tetrahydrocannabinol in oral fluid collected with StatSure, Quantisal, or Certus collector. | Q46966079 |
| | Economic and cultural correlates of cannabis use among mid-adolescents in 31 countries | Q47226146 |
| | Determination of cannabinoids in water and human saliva by solid-phase microextraction and quadrupole ion trap gas chromatography/mass spectrometry | Q47330710 |
| | Oral fluid testing for illicit substance use in preanaesthetic care | Q48177406 |
| | The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors | Q48178486 |
| | Analytical evaluation of four on-site oral fluid drug testing devices | Q48186814 |
| | An evaluation of on-site oral fluid drug screening devices DrugWipe 5+ and Rapid STAT using oral fluid for confirmation analysis | Q48269369 |
| | HPLC-MS determination of delta9-tetrahydrocannabiol in human body samples | Q48389785 |
| | Marijuana, alcohol and actual driving performance | Q48458471 |
| | Cannabis use to enhance sportive and non-sportive performances among French sport students | Q48481439 |
| | Confirmation by LC-MS of drugs in oral fluid obtained from roadside testing. | Q48579876 |
| | Development and validation of the Cozart DDS oral fluid collection device | Q48584031 |
| | Patterns of cannabis use among patients with multiple sclerosis | Q48590879 |
| | Acute and residual effects of alcohol and marijuana, alone and in combination, on mood and performance | Q48840308 |
| | Cognition and motor control as a function of Delta9-THC concentration in serum and oral fluid: limits of impairment | Q48932960 |
| | DUID: oral fluid and blood confirmation compared in Belgium. | Q49024121 |
| | To test or not to test: do workplace drug testing programs discourage employee drug use? | Q50153345 |
| | Presence of psychoactive substances in oral fluid from randomly selected drivers in Denmark. | Q50556328 |
| | A validated method for the detection of Delta 9-tetrahydrocannabinol and 11-nor-9-carboxy- Delta 9-tetrahydrocannabinol in oral fluid samples by liquid chromatography coupled with quadrupole-time-of-flight mass spectrometry. | Q50975225 |
| | Evaluation of ten oral fluid point-of-collection drug-testing devices. | Q51037309 |
| | Drug screening of preserved oral fluid by liquid chromatography-tandem mass spectrometry. | Q51095423 |
| | Recovery of drugs of abuse from the Immunalysis Quantisal oral fluid collection device. | Q51099981 |
| | Assay of Delta9-tetrahydrocannabinol (THC) in oral fluid-evaluation of the OraSure oral specimen collection device. | Q51172312 |
| | Drugs in oral fluid in randomly selected drivers. | Q51744586 |
| | Detection of drugs in saliva of impaired drivers | Q51849757 |
| | Comparison of self-reports and biological measures for alcohol, tobacco, and illicit drugs consumption in psychiatric inpatients. | Q51902113 |
| | Metabolism of tetrahydrocannabinol by the small intestine. | Q53933559 |
| | Detection of drugs of abuse in simultaneously collected oral fluid, urine and blood from Norwegian drug drivers. | Q54050683 |
| | The medicinal use of cannabis in the UK: results of a nationwide survey. | Q55040827 |
| | Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. | Q55043235 |
| | The incidence of drugs of impairment in oral fluid from random roadside testing | Q57838161 |
| | The prevalence of drugs in injured drivers | Q57986605 |
| | A rapid and sensitive method for the identification of delta-9-tetrahydrocannabinol in oral fluid by liquid chromatography–tandem mass spectrometry | Q59343299 |
| | Evaluation of four oral fluid devices (DDS®, Drugtest 5000®, Drugwipe 5+® and RapidSTAT®) for on-site monitoring drugged driving in comparison with UHPLC–MS/MS analysis | Q59652789 |
| | A simple and reliable procedure for the determination of psychoactive drugs in oral fluid by gas chromatography–mass spectrometry | Q60586206 |
| | Regulation of Bone Mass, Osteoclast Function, and Ovariectomy-Induced Bone Loss by the Type 2 Cannabinoid Receptor | Q64447692 |
| | Correlation of creatinine levels in saliva and plasma in normal subjects and renal patients | Q67558806 |
| | Importance of creatinine analyses of urine when screening for abused drugs | Q68033498 |
| | Effects of nine different chewing-gums and lozenges on salivary flow rate and pH | Q68202406 |
| | Detection of delta 9-tetrahydrocannabinol in saliva of men by means of thin-layer chromatography and mass spectrometry | Q68789019 |
| P433 | issue | 1-2 | |
| P921 | main subject | cannabinoids | Q422936 |
| P304 | page(s) | 88-111 | |
| P577 | publication date | 2013-08-25 | |
| P1433 | published in | Drug Testing and Analysis | Q3040088 |
| P1476 | title | Current knowledge on cannabinoids in oral fluid | |
| P478 | volume | 6 | |